WallStreetZenWallStreetZen

NASDAQ: KPRX
Kiora Pharmaceuticals Inc Stock

$0.53-0.02 (-3.64%)
Updated May 28, 2024
KPRX Price
$0.53
Fair Value Price
$0.48
Market Cap
$14.02M
52 Week Low
$0.45
52 Week High
$2.16
P/E
-0.48x
P/B
0.4x
P/S
1.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.00M
Earnings
$2.81M
Gross Margin
100%
Operating Margin
18.18%
Profit Margin
14.2%
Debt to Equity
0.22
Operating Cash Flow
$7M
Beta
0.75
Next Earnings
May 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A

KPRX Overview

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KPRX ($0.53) is overvalued by 10.13% relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KPRX ($0.53) is not significantly undervalued (10.13%) relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KPRX due diligence checks available for Premium users.

Be the first to know about important KPRX news, forecast changes, insider trades & much more!

KPRX News

Valuation

KPRX fair value

Fair Value of KPRX stock based on Discounted Cash Flow (DCF)
Price
$0.53
Fair Value
$0.48
Overvalued by
9.31%
KPRX ($0.53) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KPRX ($0.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KPRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.48x
Industry
17.21x
Market
32.52x

KPRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.4x
Industry
6.01x
KPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KPRX's financial health

Profit margin

Revenue
$16.0M
Net Income
$13.5M
Profit Margin
84.1%
KPRX's Earnings (EBIT) of $2.91M... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$42.4M
Liabilities
$7.5M
Debt to equity
0.22
KPRX's short-term assets ($33.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KPRX's short-term assets ($33.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KPRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$13.6M
Investing
$0.0
Financing
$15.2M
KPRX's operating cash flow ($7.14M)... subscribe to Premium to read more.
Debt Coverage Financials

KPRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KPRX$14.02M-2.20%-0.48x0.40x
XTLB$14.22M0.00%-8.70x6.41x
IMNN$13.82M-2.65%-0.73x1.63x
EDSA$13.69M-2.83%-1.80x3.17x
EVAX$14.51M-5.20%-0.47x-3.07x

Kiora Pharmaceuticals Stock FAQ

What is Kiora Pharmaceuticals's quote symbol?

(NASDAQ: KPRX) Kiora Pharmaceuticals trades on the NASDAQ under the ticker symbol KPRX. Kiora Pharmaceuticals stock quotes can also be displayed as NASDAQ: KPRX.

If you're new to stock investing, here's how to buy Kiora Pharmaceuticals stock.

What is the 52 week high and low for Kiora Pharmaceuticals (NASDAQ: KPRX)?

(NASDAQ: KPRX) Kiora Pharmaceuticals's 52-week high was $2.16, and its 52-week low was $0.45. It is currently -75.28% from its 52-week high and 18.4% from its 52-week low.

How much is Kiora Pharmaceuticals stock worth today?

(NASDAQ: KPRX) Kiora Pharmaceuticals currently has 26,256,197 outstanding shares. With Kiora Pharmaceuticals stock trading at $0.53 per share, the total value of Kiora Pharmaceuticals stock (market capitalization) is $14.02M.

Kiora Pharmaceuticals stock was originally listed at a price of $3,600.00 in Feb 13, 2015. If you had invested in Kiora Pharmaceuticals stock at $3,600.00, your return over the last 9 years would have been -99.99%, for an annualized return of -62.45% (not including any dividends or dividend reinvestments).

How much is Kiora Pharmaceuticals's stock price per share?

(NASDAQ: KPRX) Kiora Pharmaceuticals stock price per share is $0.53 today (as of May 28, 2024).

What is Kiora Pharmaceuticals's Market Cap?

(NASDAQ: KPRX) Kiora Pharmaceuticals's market cap is $14.02M, as of May 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kiora Pharmaceuticals's market cap is calculated by multiplying KPRX's current stock price of $0.53 by KPRX's total outstanding shares of 26,256,197.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.